VYNE (VYNE Therapeutics) FCF Margin % : -7,033.06% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is VYNE Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. VYNE Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-8.51 Mil. VYNE Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.12 Mil. Therefore, VYNE Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was -7,033.06%.

As of today, VYNE Therapeutics's current FCF Yield % is -79.74%.

The historical rank and industry rank for VYNE Therapeutics's FCF Margin % or its related term are showing as below:

VYNE' s FCF Margin % Range Over the Past 10 Years
Min: -6121.59 Med: -653.53 Max: -340.65
Current: -6107.51

During the past 9 years, the highest FCF Margin % of VYNE Therapeutics was -340.65%. The lowest was -6121.59%. And the median was -653.53%.

VYNE's FCF Margin % is ranked worse than
89.67% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs VYNE: -6107.51

VYNE Therapeutics FCF Margin % Historical Data

The historical data trend for VYNE Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VYNE Therapeutics FCF Margin % Chart

VYNE Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-653.53

-6,054.46

-6,121.59

-5,976.65

VYNE Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-4,519.30	-6,759.21	-8,144.90	-4,283.33	-7,033.06

Competitive Comparison of VYNE Therapeutics's FCF Margin %

For the Biotechnology subindustry, VYNE Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VYNE Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where VYNE Therapeutics's FCF Margin % falls into.

VYNE Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

VYNE Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-25.341	/	0.424
	=	-5,976.65 %

VYNE Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-8.51	/	0.121
	=	-7,033.06 %

VYNE Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of VYNE Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

VYNE Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VYNE Therapeutics Inc (NAS:VYNE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

685 Route 202/206 North, Suite 301, Bridgewater, NJ, USA, 08807

Website

https://www.vynetherapeutics.com

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Executives

Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Mutya Harsch	officer: Chief Legal Officer and GC	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Tyler Zeronda	officer: Interim CFO	C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807
Andrew Saik	officer: Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
Rex Bright	director	5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart	officer: Chief Scientific Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski	director, officer: President and CEO	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley	officer: Chief Commercial Officer	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Anthony D Bruno	director	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Hirsch	director	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Ilan Hadar	officer: CFO and Country Manager	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003